Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations

Seminars in Oncology

Volumn 32, Issue SUPPL. 10, 2005, Pages

  Jänne, Pasi A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PLACEBO;

ADENOCARCINOMA; CLINICAL TRIAL; DOSE RESPONSE; ETHNIC DIFFERENCE; HUMAN; LUNG NON SMALL CELL CANCER; MUTATION; PRIORITY JOURNAL; REVIEW; SMOKING; SOMATIC MUTATION; SURVIVAL; TUMOR REGRESSION;

EID: 31644440529     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.005     Document Type: Article

References (54)

1. D.S. Salomon, R. Brandt, F. Ciardiello Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
2. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol Ther 82 1999 241 250
3. J. Mendelsohn, J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
4. V. Rusch, J. Baselga, C. Cordon-Cardo Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Res 53 1993 2379 2385
5. G. Fontanini, M. De Laurentiis, S. Vignati Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer Amphiregulin and microvessel count are independent prognostic indicators of survival Clin Cancer Res 4 1998 241 249
6. J. Brabender, K.D. Danenberg, R. Metzger Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival Clin Cancer Res 7 2001 1850 1855
7. Y. Ohsaki, S. Tanno, Y. Fujita Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression Oncol Rep 7 2000 603 607
8. M. Volm, W. Rittgen, P. Drings Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas Br J Cancer 77 1998 663 669
9. A.P. Meert, B. Martin, P. Delmotte The role of EGF-R expression on patient survival in lung cancer A systematic review with meta-analysis Eur Respir J 20 2002 975 981
10. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246
11. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial JAMA 290 2003 2149 2158
12. R. Perez-Soler, A. Chachoua, L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
13. N. Thatcher Results of a phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. ISEL Investigators American Association for Cancer Research 96th Annual Meeting 2005 abstr LB-6
14. R.S. Herbst, G. Giaccone, J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer A phase III trial-INTACT 2 J Clin Oncol 22 2004 785 794
15. G. Giaccone, R.S. Herbst, C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer A phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784
16. R.S. Herbst, D. Prager, R. Hermann TRIBUTE- A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2004 617 abstr 7011
17. U. Gatzmeier, A. Pluzanska, A. Szczesna Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2004 619 abstr 7010
18. V.A. Miller, M.G. Kris, N. Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 2004 1103 1109
19. P.A. Janne, S. Gurubhagavatula, B.Y. Yeap Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study Lung Cancer 44 2004 221 230
20. A. Haringhuizen, H. van Tinteren, H.F. Vaessen Gefitinib as a last treatment option for non-small-cell lung cancer Durable disease control in a subset of patients Ann Oncol 15 2004 786 792
21. G.R. Simon, J.C. Ruckdeschel, C. Williams Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer Experience from a single institution Cancer Control 10 2003 388 395
22. A. Argiris, N. Mittal Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer Lung Cancer 43 2004 317 322
23. J. Park, B.B. Park, J.Y. Kim Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer Clin Cancer Res 10 2004 4383 4388
24. F. Shepherd, J. Pereira, T. Ciuleanu A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy Proc Am Soc Clin Oncol 23 2004 abstr 7022
25. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
26. V. Miller, R. Herbst, D. Prager Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy Subgroup analysis of TRIBUTE Proc Am Soc Clin Oncol 22 2004 628 abstr 7061
27. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
28. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
29. R. Bailey, M. Kris, M. Wolf Gefitinib ('Iressa'; ZD1839) monotherapy for pretreated advanced non-small cell lung cancer in IDEAL 1 and 2 Tumor response is not clinically relevantly predictable from tumor EGFR membrane staining along Lung Cancer 41 2003 71
30. H. Shigematsu, L. Lin, T. Takahashi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
31. T. Mitsudomi, T. Kosaka, H. Endoh Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 2005 2513 2520
32. S.W. Han, T.Y. Kim, P.G. Hwang Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2005 2493 2501
33. A. Marchetti, C. Martella, L. Felicioni EGFR mutations in non-small-cell lung cancer Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 2005 857 865
34. S.F. Huang, H.P. Liu, L.H. Li High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan Clin Cancer Res 10 2004 8195 8203
35. T. Kosaka, Y. Yatabe, H. Endoh Mutations of the epidermal growth factor receptor gene in lung cancer Biological and clinical implications Cancer Res 64 2004 8919 8923
36. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
37. T. Takano, Y. Ohe, H. Sakamoto Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer J Clin Oncol 2005 Epub ahead of print
38. H. Cortes-Funes, C. Gomez, R. Rosell Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients Ann Oncol 16 2005 1081 1086
39. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
40. F.A. Shepherd, J. Dancey, R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
41. B.E. Johnson, J. Lucca, M.S. Rabin Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma Proc Am Soc Clin Oncol 22 2004 633 abstr 7080
42. M.S. Tsao, A. Sakurada, J.C. Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
43. F. Cappuzzo, F.R. Hirsch, E. Rossi Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 2005 643 655
44. Tarceva 2005 Genentech, Inc South San Francisco, CA package insert
45. G.M. Clark, D. Zborowski, P. Santabárbara Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression Proc Am Soc Clin Oncol 23 2005 628s abstr 7033
46. S. Tracy, T. Mukohara, M. Hansen Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255 Cancer Res 64 2004 7241 7244
47. J. Amann, S. Kalyankrishna, P.P. Massion Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer Cancer Res 65 2005 226 235
48. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr Epidermal growth factor receptor in non-small-cell lung carcinomas Correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 2003 3798 3807
49. F. Hirsch, M. Varella-Garcia, J. McCoy Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes A Southwest Oncology Group Study J Clin Oncol 2005 Epub ahead of print
50. B. Johnson, P. Janne Selecting patients for epidermal growth factor receptor inhibitor treatment A FISH story or a tale of mutations? J Clin Oncol 2005 Epub ahead of print
51. X. Zhao, B.A. Weir, T. LaFramboise Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis Cancer Res 65 2005 5561 5570
52. J.A. Engelman, P.A. Janne, C. Mermel ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Proc Natl Acad Sci U S A 102 2005 3788 3793
53. F. Cappuzzo, E. Magrini, G.L. Ceresoli Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 2004 1133 1141
54. D.B. Solit, Y. She, J. Lobo Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel Clin Cancer Res 11 2005 1983 1989